相关实验视频

Updated: Jun 11, 2025

Animal Models of Depression - Chronic Despair Model CDM

Animal Models of Depression - Chronic Despair Model CDM

Published on: September 23, 2021

动物抑郁模型和抗抑郁药治疗的比较有效性:系统性审查和元分析

Piotr Ratajczak¹, Jakub Martyński¹, Jan Kazimierz Zięba²

¹Department of Pharmacoeconomics and Social Pharmacy, Poznan University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland.

|September 28, 2024

概括

慢性不可预测的轻度压力 (CUMS) 模型和Wistar/Sprague-Dawley大鼠在抑郁症研究中普遍存在. 选择性血清素再吸收抑制剂,如素,有效地减少不运动时间,但需要改进方法.

科学领域:

精神病疾病研究研究精神病疾病
神经科学和行为科学神经科学和行为科学
药理学研究药理学研究

背景情况:

动物模型对于理解精神疾病,特别是抑郁症至关重要,但没有一个完全复制人类与压力相关的条件.
临床前研究在很大程度上依赖于动物研究,以获得对抑郁症机制的药理见解,需要对现有数据进行系统审查.
动物行为研究允许控制环境因素,提高了研究结果对人类患者治疗的可转化性.

研究的目的:

在临床前抑郁研究中,系统地审查和元分析动物抑郁模型 (ADM) 和特定大鼠菌株的疗效.
评估选择性血清素再吸收抑制剂 (SSRI) 在减少ADM的不运动时间 (IT) 的有效性.
评估使用ADM进行抗抑郁药物测试的研究的质量,偏差风险和数据可用性.

主要方法:

进行了从PubMed,Embase和Web of Science (截至2022年12月) 识别的25项主要研究的系统审查和元分析.
在二次研究中使用PRISMA和Cochrane方法,在动物研究中使用CAMARADES方法,评估研究质量 (ARRIVE) 和偏差风险 (SYRCLE).
分析了SSRI (fluoxetine,sertraline,paroxetine,citalopram,escitalopram) 的强制游泳测试中的不运动时间 (IT) 数据,并评估了数据的可用性.

主要成果:

慢性不可预测的轻度压力 (CUMS) 模型和Wistar/Sprague-Dawley大鼠菌株是临床前抑郁症研究中最常用的.
所有分析的SSRI,尤其是fluoxetine,都在减少静止时间 (IT) 中表现出有效性;然而,研究显示中等质量和偏差高风险 (盲目,随机结果评估).
数据的有限可用性是一个重大问题,只有2.35%的作者回应了数据请求,这阻碍了许多论文的精确IT分析.

结论:

CUMS模型和特定的老鼠菌株在抑郁症研究中占主导地位,证实了SSRI的有效性,但强调了方法严谨性和透明度的关键需求.
严重的偏差风险和中间研究质量需要改进实验设计和报告标准,以提高可靠性.
增加数据的可用性和遵守严格的评估标准对于提高动物模型在抑郁症研究中的有效性和翻译潜力至关重要.

关键词:

动物抑郁模型动物抑郁模型慢性不可预测的轻度压力.数据可用性数据的可用性.克塞提因 (fluoxetine) 是一种含有素的药物.这是一个元分析.它们是老鼠菌株,老鼠菌株.选择性血清素再吸收抑制剂选择性血清素再吸收抑制剂系统性审查系统性审查

更多相关视频

A New Method for Inducing a Depression-Like Behavior in Rats

A New Method for Inducing a Depression-Like Behavior in Rats

Published on: February 22, 2018

The Mouse Forced Swim Test

The Mouse Forced Swim Test

Published on: January 29, 2012

相关概念视频

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Depression: Overview

Depression: Overview

Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...

Depressive Disorders: Etiology

Depressive Disorders: Etiology

Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...